(carglumic acid) to treat hyperammonaemia due to one of the three main organic acidaemias (isovaleric acidaemia, methylmalonic acidaemia or propionic acidaemia). Carbaglu

(ii) they are solely responsible for the content, accuracy and originality of the

Statements contained in this release, other than historical cts, are forward-looking statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). These statements are baseeastern healRECORDATI: APPROVAL GRANTED FOR THE USE OF CARBAGLU® IN THE TREATMENT OF ORGANIC ACIDAEMIASd on currently available information, on current best estimates, and on assumptions believed to be reasonable. This information, these estimates and assumptions may prove to be incomplete or erroneous, and involve numerous risks and uncertainties, beyond the Companys control. Hence, actual results may differ materially from those expressed or implied by such forward-looking statements. All mentions and descriptions of Recordati products are intended solely as information on the general nature of the companys activities and are not intended to indicate the advisability of administering any product in any particular instance.

is rapidly effective in decreasing hyperammonaemia and stabilising clinical symptoms. These data analysis led to the approval of extended indications for Carbaglu

The acute hyperammonaemia due to OA represents a true medical emergency and its management is usually performed in intensive care units. The main goal of emergency treatment is to reduce ammonia levels and thus prevent brain damage. Carbaglu

Source: RECORDATI via Thomson Reuters ONE

The owner of this announcement warrants that:

Recordati, established in 1926, is a European pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271),with a total staff of over 2,800, dedicated to the research, development, manucturing and marketing of pharmaceuticals. It has headquarters in Milan, Italy, operations in the main European countries, and a growing presence in the new markets of Central and Eastern Europe.  A European field force of around 1,400 medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordatis current and growing coverage of the European pharmaceutical market makes it a partner of choice for new product licenses from companies which do not have European marketing organizations.  Recordati is committed to the research and development of new drug entities within the cardiovascular and urogenital therapeuteastern health systemsic areas and of treatments for rare diseases.  Consolidated revenue for 2010 was € 728.1 million, operating income was € 154.8 million and net income was € 108.6 million.

has orphan drug designation and since 2003 is indicated in the treatment of NAGS deficiency.

Organic acidaemias (OA) are usually diagnosed in inncy. These rare disorders vary in their prognosis, from manageable to tal, and usually affect more than one organ system, especially the central nervous system. Organic acidaemias are a group of inherited rare metabolic disorders which disrupt physiologic amino acid degradation causing a build-up of organic acids, which in turn may inhibit the urea cycle function, leading to hyperammonaemia. It is estimated that there are about 800 patients suffering from hyperammonaemia due to those three OAs in Europe.

This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

restores the urea cycle and thus reduces blood ammonia level. Orphan Europe has performed a retrospective analysis on 57 patients to analyze the effect of Carbaglu

Thomson Reuters is the worlds largest international news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires ir presentation and disclosure of relevant interests.

social-links background-color: f8f8f8; border: 1px solid d5d5d5; margin-bottom: 20 padding-bottom: 8 float:leftsocial-links h3 font-size: 14 text-transform: none; text-align: left; padding: 8 margin: 0social-links ul clear:both; margin:0; padding:0; width: auto; padding: 0 9 float:leftsocial-links li border: 1px solid e5e5e5; background-color: ffffff; width: 64 height: 64 float: left; margin: 0 5px 0 0; padding: 0; text-align: centersocial-links li.last margin-right: 0social-links li.cebook background: FFFFFF url(/resources_v2/images/btn_social_link_cebook.gif) no-repeat center 10social-links li.twitter background: FFFFFF url(/resources_v2/images/btn_social_link_twitter.gif) no-repeat center 10social-links li.rss background: FFFFFF url(/resources_v2/images/btn_social_link_rss.gif) no-repeat center 10social-links li.youtube background: FFFFFF url(/resources_v2/images/btn_social_link_youtube.gif) no-repeat center 10social-links li a font-size: 11 font-weight: normal; padding-top: 40 display: block

eastern healRECORDATI: APPROVAL GRANTED FOR THE USE OF CARBAGLU® IN THE TREATMENT OF ORGANIC ACIDAEMIAS,Milan, 31 May 2011 – Recordati announces that its wholly-owned subsidiary Orphan Europe has received an approval from the European Commission (Directorate health systems and products) to extend the use of Carbaglu

NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

information contained therein.

(i) the releases contained herein are protected by copyright and other applicable laws; and

Leave a Reply